Ultralife (NASDAQ:ULBI) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

Ultralife Corporation (NASDAQ:ULBI) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.34 and traded as high as $6.68. Ultralife shares last traded at $6.50, with a volume of 12,879 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings raised Ultralife from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Ultralife Price Performance

The firm has a 50 day moving average price of $6.85 and a 200 day moving average price of $6.34. The company has a quick ratio of 1.23, a current ratio of 2.56 and a debt-to-equity ratio of 0.34. The stock has a market cap of $108.29 million, a P/E ratio of -13.00 and a beta of 0.75.

Ultralife (NASDAQ:ULBI) last posted its quarterly earnings data on Friday, May 8th. The technology company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.18). Ultralife had a positive return on equity of 1.15% and a negative net margin of 4.37%.The company had revenue of $47.45 million during the quarter, compared to the consensus estimate of $52.40 million.

Insider Transactions at Ultralife

In other Ultralife news, Director Bradford T. Whitmore bought 67,302 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were bought at an average price of $6.81 per share, with a total value of $458,326.62. Following the purchase, the director owned 2,050,637 shares of the company’s stock, valued at $13,964,837.97. This trade represents a 3.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders purchased 108,878 shares of company stock worth $714,928. 42.90% of the stock is currently owned by company insiders.

Institutional Trading of Ultralife

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC raised its stake in Ultralife by 2.0% during the 1st quarter. Janney Montgomery Scott LLC now owns 518,000 shares of the technology company’s stock valued at $3,377,000 after purchasing an additional 10,200 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Ultralife by 210.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 219,018 shares of the technology company’s stock valued at $1,494,000 after purchasing an additional 148,542 shares during the period. Raymond James Financial Inc. raised its stake in Ultralife by 14.5% during the 2nd quarter. Raymond James Financial Inc. now owns 116,085 shares of the technology company’s stock valued at $1,042,000 after purchasing an additional 14,667 shares during the period. Teton Advisors LLC bought a new stake in Ultralife during the 3rd quarter valued at approximately $752,000. Finally, Ancora Advisors LLC raised its stake in Ultralife by 24.3% during the 3rd quarter. Ancora Advisors LLC now owns 105,321 shares of the technology company’s stock valued at $718,000 after purchasing an additional 20,562 shares during the period. Institutional investors own 30.68% of the company’s stock.

Ultralife Company Profile

Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.